ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
AstraZeneca Pharma India reported receiving an ESG rating of 64 from Crisil ESG Ratings. The assessment was independently prepared using publicly available information.
AstraZeneca Pharma India has been assigned an ESG rating of 57 by Crisil ESG Ratings based on publicly available information.
AstraZeneca Pharma India Ltd filed its quarterly shareholding pattern for the period ended June 30, 2026, as required under SEBI regulations.
AstraZeneca Pharma India Limited filed its Annual Secretarial Compliance Report for the year ended March 31, 2026. The report confirms overall regulatory compliance with no new penalties.
AstraZeneca Pharma India updated its list of Key Managerial Personnel authorized to determine event materiality. This administrative disclosure ensures compliance with SEBI Listing Obligations.